Trump Nominates Dr. Erica Schwartz as CDC Director, Third Attempt After Vaccine Skeptics Failed

President Trump has nominated Dr. Erica Schwartz, a retired rear admiral in the U.S. Public Health Service Commissioned Corps and former deputy surgeon general, as the new director of the Centers for Disease Control and Prevention — his third nominee for the post and the first with broad support from public health professionals after two previous picks collapsed under scrutiny of their records on vaccine safety.

Schwartz, a board-certified preventive medicine physician, was nominated on April 16, 2026. She brings an unusually comprehensive academic and clinical background to the nomination: a medical degree from Brown University, a law degree from the University of Maryland, and a master's in public health from the Uniformed Services University of the Health Sciences. Before her service as deputy surgeon general during Trump's first administration, she served as chief medical officer of the United States Coast Guard, where she oversaw the medical readiness of the service's active-duty force and dependents across dozens of bases and cutters.

Her nomination is being read by public health observers as a deliberate course correction by the administration. Trump's first nominee for CDC director, Dr. David Weldon, a former Republican congressman who had expressed skepticism about childhood vaccines and the CDC's own guidance, withdrew from consideration in May 2024 after it became clear he lacked enough Senate votes to be confirmed. A second nominee was also withdrawn for similar reasons. Schwartz's record on vaccines is strongly supportive of the established scientific consensus — a fact that Senate Democrats signaled they welcomed while reserving judgment on the full scope of her policy positions.

The CDC has operated without a Senate-confirmed director for more than two years, functioning under acting leadership during a period of significant institutional turbulence. The agency saw deep budget cuts in 2025, the reassignment of hundreds of career scientists, and the reorganization of several key divisions under the broader restructuring of the Department of Health and Human Services carried out by the Department of Government Efficiency. Critics have argued that these changes have degraded the CDC's ability to respond to emerging infectious disease threats, conduct epidemiological surveillance, and communicate science-based public health guidance independently.

Schwartz has not yet given public testimony about her priorities for the agency, but administration sources described her as committed to restoring stability and operational effectiveness to an institution whose credibility has been contested across multiple political cycles. Her background in preventive medicine and her record of managing complex public health logistics within the Coast Guard were cited by administration officials as evidence of the practical leadership skills the CDC needs.

She will face confirmation hearings before the Senate Health, Education, Labor and Pensions Committee, chaired by Senator Bill Cassidy of Louisiana, a physician who has previously expressed frustration with the CDC's handling of COVID-19 guidance and its communication strategies. The confirmation timeline has not been set, but administration officials have expressed hope for a vote before the summer recess. Several public health advocacy organizations, including the American Public Health Association and the Infectious Diseases Society of America, issued statements welcoming the nomination and calling for rapid confirmation to restore stable leadership at the agency.